Precision medicine's inevitable trajectory toward rare-disease-sized cohorts: implications for machine learning and

Andrew Janowczyk1, Doron Merkler2, Olivier Michielin3

  • 1Department of Biomedical Engineering, Emory University, Atlanta, GA, USA; Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA; Department of Oncology, Division of Precision Oncology, University Hospitals of Geneva, Geneva, Switzerland; Department of Diagnostics, Division of Clinical Pathology, University Hospitals of Geneva, Geneva, Switzerland.

Summary

Precision medicine faces challenges with rare-disease-sized cohorts (RDSCs) due to small, fragmented datasets. New methods and systemic changes in data infrastructure are crucial for advancing personalized care.